A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms CPTC
- Sponsors Gilead Sciences
- 27 Nov 2017 Planned End Date changed from 1 May 2018 to 1 Aug 2018.
- 27 Nov 2017 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
- 23 Feb 2017 Status changed from not yet recruiting to recruiting.